US Research Body Says Covaxin Neutralises Both Alpha & Delta Variants Of Covid 19 |Breaking news|

Two studies conducted by the US' National Institute of Health (NIH) suggest that Bharat Biotech's Covaxin is effective against both Alpha and Delta variants of coronavirus.
Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), effectively neutralises both Alpha and Delta variants of coronavirus, revealed the studies recently conducted by the US' National Institute of Health (NIH), the top American health research institute.

Two studies -- Study 1 and Study 2 -- were carried out wherein blood serum from people who had received Covaxin was collected and examined. The results suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively, said NIH.

"The results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively," the NIH said in its press release.

SARS-CoV-2 is a virus that causes Covid-19 disease.

Covaxin comprises a disabled form of SARS-CoV-2 that cannot replicate but still stimulates the immune system to make antibodies against the virus, the press release said, adding that Covaxin is "safe and well-tolerated" according to the published results from a phase 2 trial of the vaccine.